BioSpace News Archive

Aerpio Pharmaceuticals, Inc. (the “Company”) (Nasdaq: ARPO), today announced that, due to the public health and safety concerns related to the novel coronavirus (COVID-19) pandemic and recommendations and orders from federal and state authorities, the location of its 2020 annual meeting has been changed to a virtual-only format.

Cancer researchers at Children’s Hospital of Philadelphia (CHOP) have harnessed tools used for the development of cancer immunotherapies and adapted them to identify regions of the SARS-CoV-2 virus to target with a vaccine, employing the same approach used to elicit an immune response against cancer cells to stimulate an immune response against the virus

Free, Online Presentation to Address Symptoms of Enlarged Prostate, Treatment Options and Tips for Managing Condition During Pandemic

Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO (gNO) for the treatment of solid tumors, today announced it will report financial results for its fiscal fourth quarter and year ended March 31, 2020 a

Retrophin, Inc. (Nasdaq: RTRX) today announced the pricing of an underwritten public offering of 6,500,000 shares of its common stock at a price to the public of $15.50 per share. All of the shares are being sold by Retrophin.

KN026 is an anti-HER2 bispecific antibody which can simultaneously bind two non-overlapping epitopes of HER2 and lead to a dual HER2 signal blockade, presumedly causing HER2 to aggregate on the cell surface and endocytose.

Replimune Group, Inc., a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, announced the pricing of its public offering of 2,826,088 shares of its common stock at a public offering price of $23.00 per share.

Lineage Cell Therapeutics to Host Therapeutic Expert Call Today to Discuss the First Known Reported Finding of Retinal Tissue Regeneration with OpRegen ® in Dry AMD with Geographic Atrophy Call Scheduled for Today at 4:30pm Eastern Time CARLSBAD, Calif.--( BUSINESS WIRE )-- Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage cell therapy company which manufactures and transplants specific cell types to treat disea

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced new findings from the phase 3 ARTEMIS trial that show patients with peanut allergy aged 4 through 17 were highly satisfied after nine months of daily treatment with PALFORZIA™ [

Almost twenty years after deciphering the human genome, our understanding of human disease is still far from complete. One of the most powerful and versatile tools to better understand biology and disease-relevant processes is the use of well-characterized small chemical modulators of protein function. The new EUbOPEN consortium aims